The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
Identifieur interne : 001041 ( Main/Exploration ); précédent : 001040; suivant : 001042The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
Auteurs : Debra L. Kiss [Australie] ; James Longden ; Gregory A. Fechner ; Vicky M. AverySource :
- Cellular & molecular biology letters ; 2009.
English descriptors
- KwdEn :
- Animals, CCR5 Receptor Antagonists, CHO Cells, Ceramides (metabolism), Chemokine CCL3 (pharmacology), Chemokine CCL5 (pharmacology), Cricetinae, Cricetulus, Endosomes (drug effects), Endosomes (metabolism), Golgi Apparatus (metabolism), Humans, Ligands, Protein Transport, Receptors, CCR5 (agonists), Receptors, CCR5 (genetics), Receptors, CCR5 (metabolism).
- MESH :
- chemical , agonists : Receptors, CCR5.
- chemical , genetics : Receptors, CCR5.
- chemical , metabolism : Ceramides, Receptors, CCR5.
- chemical , pharmacology : Chemokine CCL3, Chemokine CCL5.
- chemical : CCR5 Receptor Antagonists, Ligands.
- drug effects : Endosomes.
- metabolism : Endosomes, Golgi Apparatus.
- Animals, CHO Cells, Cricetinae, Cricetulus, Humans, Protein Transport.
Abstract
CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.
DOI: 10.2478/s11658-009-0017-1
PubMed: 19448977
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000389
- to stream PubMed, to step Curation: 000389
- to stream PubMed, to step Checkpoint: 000368
- to stream Ncbi, to step Merge: 000611
- to stream Ncbi, to step Curation: 000611
- to stream Ncbi, to step Checkpoint: 000611
- to stream Main, to step Merge: 001051
- to stream Main, to step Curation: 001041
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.</title><author><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name><affiliation wicri:level="1"><nlm:affiliation>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111</wicri:regionArea><wicri:noRegion>4111</wicri:noRegion></affiliation></author><author><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></author><author><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name></author><author><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.2478/s11658-009-0017-1</idno><idno type="RBID">pubmed:19448977</idno><idno type="pmid">19448977</idno><idno type="wicri:Area/PubMed/Corpus">000389</idno><idno type="wicri:Area/PubMed/Curation">000389</idno><idno type="wicri:Area/PubMed/Checkpoint">000368</idno><idno type="wicri:Area/Ncbi/Merge">000611</idno><idno type="wicri:Area/Ncbi/Curation">000611</idno><idno type="wicri:Area/Ncbi/Checkpoint">000611</idno><idno type="wicri:Area/Main/Merge">001051</idno><idno type="wicri:Area/Main/Curation">001041</idno><idno type="wicri:Area/Main/Exploration">001041</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.</title><author><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name><affiliation wicri:level="1"><nlm:affiliation>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111</wicri:regionArea><wicri:noRegion>4111</wicri:noRegion></affiliation></author><author><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></author><author><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name></author><author><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name></author></analytic><series><title level="j">Cellular & molecular biology letters</title><idno type="e-ISSN">1689-1392</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>CCR5 Receptor Antagonists</term><term>CHO Cells</term><term>Ceramides (metabolism)</term><term>Chemokine CCL3 (pharmacology)</term><term>Chemokine CCL5 (pharmacology)</term><term>Cricetinae</term><term>Cricetulus</term><term>Endosomes (drug effects)</term><term>Endosomes (metabolism)</term><term>Golgi Apparatus (metabolism)</term><term>Humans</term><term>Ligands</term><term>Protein Transport</term><term>Receptors, CCR5 (agonists)</term><term>Receptors, CCR5 (genetics)</term><term>Receptors, CCR5 (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Ceramides</term><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chemokine CCL3</term><term>Chemokine CCL5</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>CCR5 Receptor Antagonists</term><term>Ligands</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Endosomes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Endosomes</term><term>Golgi Apparatus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CHO Cells</term><term>Cricetinae</term><term>Cricetulus</term><term>Humans</term><term>Protein Transport</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></noCountry><country name="Australie"><noRegion><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19448977
|texte= The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19448977" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |